Compound class:
Synthetic organic
Comment: The chemical structure for nispomeben was obtained from WHO proposed INN list 131 (August 2024). The INN record describes the compound as a non-opioid analgesic. It appears that this is the INN for Novaremed's clinical lead NRD.E1/NRD135S.E1 [1]. The mode of action of NRD.E1 involves inhibition of Lyn kinase phosphorylation, and not interactions with widely exploited pain-related targets (opioid, serotonin, GABA, NMDA or cannabinoid receptors, sodium or calcium channels). The exact mechanism of action remains to be determined.
|
|
Classification ![]() |
|
Compound class | Synthetic organic |
IUPAC Name ![]() |
N-[(2S)-1-(4-hydroxyphenyl)-3-[(2S)-2-hydroxypropoxy]propan-2-yl]-3-phenylpropanamide |
International Nonproprietary Names ![]() |
|
INN number | INN |
13124 | nispomeben |
Database Links ![]() |
|
CAS Registry No. | 1443133-41-2 (source: WHO INN record) |
GtoPdb PubChem SID | 500839917 |
PubChem CID | 51033894 |
Search Google for chemical match using the InChIKey | CDKPAWCGPQDCGU-LPHOPBHVSA-N |
Search Google for chemicals with the same backbone | CDKPAWCGPQDCGU |
Search PubMed clinical trials | nispomeben |
Search PubMed titles | nispomeben |
Search PubMed titles/abstracts | nispomeben |
UniChem Compound Search for chemical match using the InChIKey | CDKPAWCGPQDCGU-LPHOPBHVSA-N |
UniChem Connectivity Search for chemical match using the InChIKey | CDKPAWCGPQDCGU-LPHOPBHVSA-N |